Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Petlife Pharmaceuticals, Inc. (OTC: PTLF).

Full DD Report for PTLF

You must become a subscriber to view this report.


Recent News from (OTC: PTLF)

PetLife Pharmaceuticals Announces Haiti Veterinary Initiative
HANCOCK, MD / ACCESSWIRE / October 19, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high- potency veterinary cancer medications and nutraceuticals for pets, through its subsidiary, PetLife Pharma International, Inc. (collectively "P...
Source: ACCESSWIRE
Date: October, 19 2017 15:00
PetLife Pharmaceuticals Gets 'On the Road Again!' With 2 Scheduled Road Shows in California
HANCOCK, MD / ACCESSWIRE / July 31, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is back on the road to bring their message of hope to pet owners in the fight a...
Source: ACCESSWIRE
Date: July, 31 2017 06:30
PetLife Pharmaceuticals' CEO, Dr. Ralph Salvagno, Issues Letter to Shareholders
HANCOCK, MD / ACCESSWIRE / July 20, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, has issued a letter to its shareholders from Ralph Salvagno, MD, CEO and Chairm...
Source: ACCESSWIRE
Date: July, 20 2017 07:01
PetLife Announces its All-natural 'Cancer Cocktail' With Applicability to Pet and Human Markets
HANCOCK, Maryland , June 14, 2017 /PRNewswire/ -- PetLife Pharmaceuticals, Inc.  (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug...
Source: PR Newswire
Date: June, 14 2017 06:00
PetLife Completes Its TV Commercial for Newly Acquired Dr. Geoff's by PetLife, Preparing for Regional Launch
Clip of TV Commercial at http://www.petlifepharma.com/drg HANCOCK, MD / ACCESSWIRE / June 6, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced to...
Source: ACCESSWIRE IA
Date: June, 06 2017 06:02
PetLife Pharmaceuticals Launches New Website
HANCOCK, MD / ACCESSWIRE / June 1, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company," "PetLife"), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced its new Website, www.petlifepharma.com . PetLife has la...
Source: ACCESSWIRE IA
Date: June, 01 2017 06:00
PetLife Management Comments on Recent Market Activity
PetLife Management Comments on Recent Market Activity
Source: OTC Markets
Date: May, 31 2017 00:00
PetLife Files for Patent for the Treatment of Cancer for Pets
Combining Chlorotoxin and Plant-based Therapeutic for VitalZul™ for Dogs and Cats HANCOCK, MD / ACCESSWIRE / May 30, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceu...
Source: ACCESSWIRE IA
Date: May, 30 2017 06:00
PetLife Explores New Scorpion Venom-Based Therapies for Growing Product Line
HANCOCK, MD / ACCESSWIRE / May 26, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that they are exploring various new products for their produc...
Source: ACCESSWIRE IA
Date: May, 26 2017 06:00
PetLife Closes Acquisition of Assets for Dr. Geoff's Real Food for Pets
The product line is projected to include VitalZul™ in a second generation of the product in 2018 HANCOCK, MD / ACCESSWIRE / May 23, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medicat...
Source: ACCESSWIRE IA
Date: May, 23 2017 06:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-210.00950.00950.00950.009510,000
2018-08-200.0090.0090.0090.00935,000
2018-08-17N/A0.008N/AN/A3
2018-08-160.00250.0080.0090.002517,011
2018-08-150.0060.0060.0060.00610,000

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2110,00010,000100.0000Short
2018-08-201,79435,0005.1257Cover
2018-08-1650017,0112.9393Cover
2018-08-138080100.0000Short
2018-08-0929,00066,00043.9394Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PTLF.


About Petlife Pharmaceuticals, Inc. (OTC: PTLF)

Logo for Petlife Pharmaceuticals, Inc. (OTC: PTLF)

PetLife Pharmaceuticals, Inc. is a registered U.S. Veterinary Pharmaceutical company whose mission is to bring its scientifically proven, bioactive medication and nutraceuticals Vitalzul to the world of veterinary oncology. The Company specializes in the research, development, sales and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis.

 

Contact Information

 

 

Current Management

  • Ralph T. Salvagno / CEO
    • Dr. Ralph Salvagno is Chairman of the Board and CEO of PetLife Pharmaceuticals Inc. From purebred Golden Retrievers to stray mixed breeds, dogs have always been a part of his life. More recently, his affinity has been for felines. A Bachelor of Science Honors graduate of the University of Maryland, Dr. Salvagno received his M.D. degree from the University of Maryland Medical School and completed an Orthopedic Surgery residency at Case Western Reserve University/ University Hospitals of Cleveland. A founding partner and president of the Center for Joint Surgery and Sports Medicine in Hagerstown, Maryland, he has recently retired to devote time and energy to PetLife Pharmaceuticals. Apart from founding his medical practice, Dr. Salvagno has exercised his entrepreneurial spirit with involvement in Medical Software, Transportation and Biotechnology ventures.Dr. Salvagno has previously served on the Board of the Washington County Arthritis Foundation and served for years on the Board of Meritus Enterprises, the forprofit arm of Meritus Medical Center. Dr. Salvagno currently serves as Vice Chief of Staff at Meritus Medical Center in Hagerstown, Md. He is Medical Director of Saving Lives Initiative Sierra Leone and recentlycompleted the first surgical mission to Sierra Leone since the Ebola crisis.
  • Vivek Ramana / Chief Med. Officer
    • Prior to joining PetLife, Dr. Ramana served as Senior Safety Medical Officer/Senior Medical Director for Ambit Biosciences. In , Dr. Ramana served as Senior Medical Director/Therapeutic Area Lead for US Astellas. From to he was Chief Medical Officer and President for AdPharma. From to , he served as Vice President, Medical Services at Ovation Pharmaceuticals. During the early part of Dr. Ramana s career, from to , Dr. Ramana served as Medical Director of R amp D for Pharmaceutical Clinical Research, Inc., which involved joint ventures with BMS, Pfizer, Schering Plough, and Astra Zeneca. . Dr. Ramana received his medical degree from the University of Belgrade, Serbia and specialized in Radiation Oncology and Clinical Pathology. Post Graduate studies in Molecular Immunology, Genetics and Molecular Biology from University of New Haven, CT PostDoctoral Studies in Clinical Pharmacology, Drug Research amp Development and Regulation from TUFTS University in Boston.
  • Ralph T. Salvagno / Chairman
    • Dr. Ralph Salvagno is Chairman of the Board and CEO of PetLife Pharmaceuticals Inc. From purebred Golden Retrievers to stray mixed breeds, dogs have always been a part of his life. More recently, his affinity has been for felines. A Bachelor of Science Honors graduate of the University of Maryland, Dr. Salvagno received his M.D. degree from the University of Maryland Medical School and completed an Orthopedic Surgery residency at Case Western Reserve University/ University Hospitals of Cleveland. A founding partner and president of the Center for Joint Surgery and Sports Medicine in Hagerstown, Maryland, he has recently retired to devote time and energy to PetLife Pharmaceuticals. Apart from founding his medical practice, Dr. Salvagno has exercised his entrepreneurial spirit with involvement in Medical Software, Transportation and Biotechnology ventures.Dr. Salvagno has previously served on the Board of the Washington County Arthritis Foundation and served for years on the Board of Meritus Enterprises, the forprofit arm of Meritus Medical Center. Dr. Salvagno currently serves as Vice Chief of Staff at Meritus Medical Center in Hagerstown, Md. He is Medical Director of Saving Lives Initiative Sierra Leone and recentlycompleted the first surgical mission to Sierra Leone since the Ebola crisis.

Current Share Structure

  • Market Cap: $650,773 - 03/09/2018
  • Authorized: 750,000,000 - 01/05/2017
  • Issue and Outstanding: 73,951,435 - 01/15/2018

 


Recent Filings from (OTC: PTLF)

Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 07 2018
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: April, 27 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: April, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: February, 12 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: January, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 18 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: January, 17 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: December, 15 2017

 

 


Daily Technical Chart for (OTC: PTLF)

Daily Technical Chart for (OTC: PTLF)


Stay tuned for daily updates and more on (OTC: PTLF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PTLF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PTLF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of PTLF and does not buy, sell, or trade any shares of PTLF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/